AVEO Pharma (AVEO) -12.5% premarket even as its Q4 net loss narrowed from the year-ago quarter,...

|About: AVEO Pharmaceuticals, Inc. (AVEO)|By:, SA News Editor

AVEO Pharma (AVEO) -12.5% premarket even as its Q4 net loss narrowed from the year-ago quarter, primarily due to a milestone from Astellas recognized upon the acceptance of a new drug filing. But AVEO also announced disappointing results for its tivozanib drug from a Phase 3 TIVO-1 study in patients with advanced renal cell carcinoma.